What are the current guidelines for the treatment and monitoring of hyperthyroidism, including antithyroid drug dosing, use in pregnancy, beta‑blocker therapy, and indications for radioactive iodine or surgery?

Hyperthyroidism Management Guidelines

Initial Evaluation and Symptomatic Management

Beta-adrenergic blockade should be initiated in elderly patients with symptomatic thyrotoxicosis, those with resting heart rates exceeding 90 bpm, or patients with coexisting cardiovascular disease 1. Consider beta-blockers for all symptomatic patients to control tachycardia, anxiety, and tremor 1, 2.

Perform radioactive iodine uptake (RAIU) when the clinical presentation is not clearly diagnostic of Graves' disease; add a thyroid scan if thyroid nodularity is present 1.

Treatment Options for Graves' Disease

Three equally acceptable treatment modalities exist for overt Graves' hyperthyroidism: radioactive iodine (RAI) therapy, antithyroid drugs (ATDs), or thyroidectomy 1. The choice depends on specific clinical scenarios and contraindications rather than patient preference alone.

Antithyroid Drug Therapy

Methimazole should be used in virtually every patient choosing ATD therapy, with the critical exception of first-trimester pregnancy when propylthiouracil (PTU) is mandatory 1. This recommendation stems from PTU's rare but potentially fatal hepatotoxicity risk, which led the FDA to restrict its use primarily to first-trimester pregnancy 1.

Standard treatment duration: 12-18 months for adults 1, 3; 24-36 months for children 1, 3.

Monitoring approach:

• Assess thyroid function monthly during active treatment
• Measure TSH receptor antibodies (TRAb) at 12-18 months
• If TRAb remains elevated at 12-18 months, either continue MMI for another 12 months or proceed to definitive therapy 3
• Approximately 50% of patients achieve remission after initial ATD course 2

Key safety consideration: Patients must be informed about agranulocytosis risk and instructed to stop medication immediately if fever or pharyngitis develops 1.

Radioactive Iodine Therapy

Administer sufficient RAI in a single dose (typically 10-15 mCi) to render the patient hypothyroid 1. This ablative approach is preferred over attempting to maintain euthyroidism, as it reduces treatment failure rates.

Pretreatment requirements:

• Beta-blockade for elderly patients or those with severe symptoms (free T4 2-3 times upper limit of normal) 1
• Consider methimazole pretreatment in high-risk patients (extremely symptomatic or severely elevated thyroid hormones), discontinuing 3-7 days before RAI administration 1
• Optimize all comorbid conditions before treatment 1
• Verify negative pregnancy test within 48 hours of treatment 1

Absolute contraindications: Pregnancy, lactation, suspected thyroid cancer, inability to comply with radiation safety precautions, and planned pregnancy within 4-6 months 1.

Follow-up protocol:

• Assess free T4 and total T3 within 1-2 months post-treatment 1
• If hyperthyroidism persists at 6 months or shows minimal response at 3 months, administer repeat RAI 1
• Approximately 80% achieve cure after 1-2 months, though permanent hypothyroidism is common 2

Surgical Management

Total or near-total thyroidectomy is the procedure of choice 1. Surgery must be performed by high-volume thyroid surgeons to minimize complications 1.

Specific indications for surgery:

• Large goiters (≥80 g) with compressive symptoms
• Suspected or confirmed thyroid malignancy
• Coexisting hyperparathyroidism requiring surgery
• Pregnancy planned within 4-6 months (before RAI would normalize thyroid function)
• Moderate to severe active Graves' orbitopathy
• Patient preference for definitive treatment without radiation exposure 1

Preoperative preparation:

• Render patient euthyroid with methimazole
• Administer potassium iodide in the immediate preoperative period 1

Pregnancy-Specific Management

Diagnosis in Pregnancy

Use serum TSH with either total T4/T3 (adjusted to 1.5 times nonpregnant range) or free T4/T3 with trimester-specific reference ranges 1. Low TSH with normal free T4 in early pregnancy represents physiologic hCG-mediated suppression and does not indicate hyperthyroidism 1.

Antithyroid Drug Selection

The critical paradigm: PTU for first trimester, methimazole for second and third trimesters 1. This approach balances PTU's teratogenic advantage (avoiding MMI-associated aplasia cutis and choanal/esophageal atresia) against its hepatotoxicity risk 1.

Specific protocols:

• Women on MMI planning pregnancy: Switch to PTU immediately upon positive pregnancy test, then back to MMI at second trimester 1
• Women started on PTU in first trimester: Switch to MMI at beginning of second trimester 1
• Treatment target: Maintain maternal thyroid hormones slightly above normal range with suppressed TSH; keep free T4 at or slightly above upper limit of nonpregnant reference range 1
• Monitor thyroid function monthly with dose adjustments as needed 1

Critical exception: Transient hCG-mediated TSH suppression in early pregnancy (gestational thyrotoxicosis/hyperemesis gravidarum) should NOT be treated with ATDs 1. Most cases resolve spontaneously; beta-blockers may provide symptomatic relief if needed 4.

TRAb Monitoring in Pregnancy

Measure TRAb at 22-26 weeks gestation in:

• Women with uncertain hyperthyroidism etiology 1
• Women previously treated with RAI or thyroidectomy for Graves' disease (measure initially in first trimester if elevated, then again at 22-26 weeks) 1
• Women diagnosed with Graves' disease during pregnancy (measure at diagnosis and again at 22-26 weeks if elevated) 1

These measurements guide neonatal monitoring decisions, as maternal TRAb crosses the placenta and can cause fetal/neonatal thyrotoxicosis 1.

Surgery During Pregnancy

If thyroidectomy is necessary, perform during the second trimester 1. Avoid first trimester (teratogenic anesthetic effects, increased fetal loss risk) and third trimester (increased preterm labor risk of 4.5-5.5%) 1.

Postpartum Considerations

Methimazole is the preferred ATD during lactation due to PTU's hepatotoxicity risk 1. Both drugs appear in breast milk in small concentrations, but studies show normal infant thyroid function and intellectual development 1. RAI remains contraindicated during breastfeeding 1.

Distinguish postpartum thyrotoxicosis from postpartum Graves' disease relapse using selective diagnostic studies; use beta-blockers judiciously for symptomatic relief 1.

Subclinical Hyperthyroidism

Strongly consider treatment when TSH is persistently <0.1 mU/L in:

• All individuals ≥65 years
• Postmenopausal women not on estrogens or bisphosphonates
• Patients with cardiac risk factors, heart disease, or osteoporosis
• Individuals with hyperthyroid symptoms 1

Consider treatment when TSH is below normal but >0.1 mU/L in:

• Individuals ≥65 years
• Patients with cardiac disease or hyperthyroid symptoms 1

Treatment should follow the same principles as overt hyperthyroidism based on etiology 1.

Pediatric Considerations

Children not in remission after 1-2 years of methimazole should be considered for RAI or thyroidectomy 1. If RAI is chosen with severely elevated thyroid hormones (total T4 >20 μg/dL or free T4 >5 ng/dL), pretreat with methimazole and beta-blockade until normalization 1. Administer sufficient RAI to render hypothyroid 1. For surgery, perform total or near-total thyroidectomy by high-volume surgeons after achieving euthyroidism with methimazole and immediate preoperative potassium iodide 1.

Graves' Ophthalmopathy Considerations

Achieve and maintain euthyroidism expeditiously in patients with Graves' orbitopathy 1. In nonsmoking patients without clinically apparent ophthalmopathy, all three treatment modalities are equally acceptable 1. For patients with mild active ophthalmopathy without risk factors, all treatments remain acceptable 1. However, if these patients choose RAI, consider concurrent corticosteroid treatment 1. Smoking cessation is mandatory—refer patients to structured cessation programs 1.